Viking Therapeutics Continues Expansion Course – Analysts Set Price Target at $93.60
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed on August 21, 2026 at $28.95, down 1.70 percent from the previous close of $29.45.
- 23 analysts recommend the stock for buy or strong buy (as of July 9, 2026), with an average price target of $93.60.
- The company had liquid funds of $502 million at the end of the second quarter of 2026.
- Lead candidate VK2735 is a dual GLP-1/GIP receptor agonist for the treatment of obesity.
- Viking Therapeutics is in the pre-revenue phase with no approved medications and reports earnings per share of -$4.66.
Viking Therapeutics Inc. (VKTX) closed on August 21, 2026 at $28.95, down 1.70 percent from the previous close of $29.45. The California-based biotech company, which focuses on developing therapies for metabolic and endocrine disorders, has a market capitalization of approximately $3.8 billion and remains in the pre-revenue phase.
Analysts Remain Optimistic – Consensus Significantly Above Current Price
The latest analyst rating from July 9, 2026 shows a distinctly positive picture: 22 analysts recommend the stock for purchase, with one additional analyst issuing a strong buy recommendation. Only one analyst rates the stock as neutral. The average price target is $93.60, with a median of $95 – representing upside potential of more than 220 percent compared to the current level. The range of price targets spans from $83 to $101.
Solid Liquidity Following Q2 Report
On July 29, 2026, Viking Therapeutics released its second quarter results. The company had liquid funds of $502 million at the end of the reporting period. As a clinical biotech company, Viking Therapeutics currently generates no revenue, with earnings per share of -$4.66 over the past twelve months. The price-to-book ratio stands at 6.22.
Pipeline Progress in Focus
At the center of the company's strategy is the lead candidate VK2735, a dual GLP-1 and GIP receptor agonist being developed for the treatment of obesity. The company focuses on metabolic and endocrine indications – an area gaining increasing importance given growing demand for innovative obesity therapies. Viking Therapeutics has no approved medications on the market to date, which corresponds to typical risks associated with biotech investments.
Technical Indicators in Neutral Range
The Relative Strength Index (RSI) stood at 47.93 points on August 21, 2026, moving in a neutral range between oversold and overbought. In the preceding trading days, the RSI fluctuated between 41.48 and 57.48 points. The stock is currently trading significantly below its 52-week high of $43.15, but above the year-to-date low of $22.96. The beta coefficient of 0.62 indicates lower volatility compared to the overall market.
Risk Warning for Investors
Viking Therapeutics is a typical clinical biotech company without market-ready products. Success depends substantially on positive study results, regulatory approvals, and successful commercialization of drug candidates. The high valuation despite absent revenue reflects investor expectations for the pipeline, but carries corresponding risks.